# Intetumumab

> Mediated Wiki article. Canonical URL: https://mediated.wiki/source/Intetumumab
> Markdown URL: https://mediated.wiki/source/Intetumumab.md
> Source: https://en.wikipedia.org/wiki/Intetumumab
> Source revision: 1157577737
> License: Creative Commons Attribution-ShareAlike 4.0 International (https://creativecommons.org/licenses/by-sa/4.0/)

{{Short description|Monoclonal antibody}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 458270895
| type              = mab
| image             =
| alt               =
| mab_type          = mab
| source            = u
| target            = [integrin](/source/integrin) alpha-V
| tradename         = 
| Drugs.com         =
| MedlinePlus       =
| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      = <!-- A / B            / C / D / X -->
| pregnancy_category= 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status      =
| routes_of_administration =
| bioavailability   =
| protein_bound     =
| metabolism        =
| elimination_half-life =
| excretion         =
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number        = 725735-28-4
| ATC_prefix        = none
| ATC_suffix        =
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = GQE1BJE2NI
| PubChem           =
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank          =
| KEGG = D09631
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| C=6468 | H=10008 | N=1744 | O=2006 | S=40
}}

'''Intetumumab''' is a human [monoclonal antibody](/source/monoclonal_antibody) targeting [integrin](/source/integrin)s<ref name="pmid30451118">{{cite journal | vauthors = Łasiñska I, Mackiewicz J | title = Integrins as A New Target for Cancer Treatment | journal = Anti-Cancer Agents in Medicinal Chemistry | volume = 19 | issue = 5 | pages = 580–586 | date = 2019 | pmid = 30451118 | doi = 10.2174/1871520618666181119103413 | s2cid = 53952455 }}</ref> that was being studied for the treatment of solid tumors.<ref>{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Intetumumab|publisher=[American Medical Association](/source/American_Medical_Association)|url=http://www.ama-assn.org/ama1/pub/upload/mm/365/intetumumab.pdf}}</ref>

Intetumumab was developed by [Centocor](/source/Centocor), Inc.

Phase II clinical trials for treatment of [melanoma](/source/melanoma) and [prostate cancer](/source/prostate_cancer) were in progress when development of the drug was discontinued.<ref name="Adis">{{cite web|title=Intetumumab|url=http://adisinsight.springer.com/drugs/800019252|website=AdisInsight|access-date=30 January 2017}}</ref>

== References ==

<references />

{{monoclonals for tumors}}

Category:Janssen Biotech
Category:Experimental cancer drugs

{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}

---
Adapted from the Wikipedia article [Intetumumab](https://en.wikipedia.org/wiki/Intetumumab) by Wikipedia contributors ([contributor history](https://en.wikipedia.org/wiki/Intetumumab?action=history)). Available under [Creative Commons Attribution-ShareAlike 4.0 International](https://creativecommons.org/licenses/by-sa/4.0/). Changes may have been made.